Zobrazeno 1 - 10
of 109
pro vyhledávání: '"Julie N Graff"'
Autor:
Yiyi Chen, William L Redmond, Tomasz M Beer, Julie N Graff, Joshi J Alumkal, Rachel E Slottke, George V Thomas, Reid F Thompson, Mary A Wood, Emile Latour, Raymond C Bergan, Amy E Moran
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background Checkpoint inhibitors can induce profound anticancer responses, but programmed cell death protein-1 (PD-1) inhibition monotherapy has shown minimal activity in prostate cancer. A published report showed that men with prostate cancer who we
Externí odkaz:
https://doaj.org/article/040509c77c06444f90e082d68bfd329b
Author Correction: Evolution of structural rearrangements in prostate cancer intracranial metastases
Autor:
Francesca Khani, William F. Hooper, Xiaofei Wang, Timothy R. Chu, Minita Shah, Lara Winterkorn, Michael Sigouros, Vincenza Conteduca, David Pisapia, Sara Wobker, Sydney Walker, Julie N. Graff, Brian Robinson, Juan Miguel Mosquera, Andrea Sboner, Olivier Elemento, Nicolas Robine, Himisha Beltran
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/5cbc5bff8e0144b2828d406b46650b79
Autor:
Karen A. Autio, Emmanuel S. Antonarakis, Tina M. Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan, Michael J. Morris, Susan F. Slovin, Elisabeth I. Heath, Scott T. Tagawa, Dana E. Rathkopf, Matthew I. Milowsky, Michael R. Harrison, Tomasz M. Beer, Arjun V. Balar, Andrew J. Armstrong, Daniel J. George, Channing J. Paller, Arlyn Apollo, Daniel C. Danila, Julie N. Graff, Luke Nordquist, Erica S. Dayan Cohn, Kin Tse, Nicole A. Schreiber, Glenn Heller, Howard I. Scher
Publikováno v:
European Urology Open Science, Vol 34, Iss , Pp 70-78 (2021)
Background: Phase 2 trial endpoints that can be utilized in high-risk biochemical recurrence (BCR) after prostatectomy as a way of more rapidly identifying treatments for phase 3 trials are urgently needed. The efficacy of abiraterone acetate plus pr
Externí odkaz:
https://doaj.org/article/7cb29db5a1d04ef391276d51f770d34a
Autor:
Lauren B. Peiffer, James R. White, Carli B. Jones, Rachel E. Slottke, Sarah E. Ernst, Amy E. Moran, Julie N. Graff, Karen S. Sfanos
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 32, Iss , Pp 100822- (2022)
Recent studies in cancer patients and animal models demonstrate that intestinal microbiota influence the therapeutic efficacy of cancer treatments, including immune checkpoint inhibition. However, no studies to-date have investigated relationships be
Externí odkaz:
https://doaj.org/article/e3769f5586d74baa8303d87a6c921ba4
Autor:
Julie N. Graff, Mark N. Stein, Rishi Surana, Luai Al Rabadi, Eric Liu, Lawrence Fong, Shawna Bailey, Emile Latour, Timothy A. Newby, Amy E. Moran, Tomasz M. Beer
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Background: Phase 3 studies of immune checkpoint inhibitors have not shown a survival benefit in prostate cancer, but some patients have a profound anticancer response.Patients and Methods: We evaluated the efficacy of the CTLA-4 targeted agent, ipil
Externí odkaz:
https://doaj.org/article/a0ffdd59fa0b4fb68cbe0074fba89eec
Autor:
Alexandra O. Sokolova, Julie N. Graff
Publikováno v:
JAMA Oncology.
Autor:
Anis A. Hamid, Nicolas Sayegh, Bertrand Tombal, Maha Hussain, Christopher J. Sweeney, Julie N. Graff, Neeraj Agarwal
Publikováno v:
American Society of Clinical Oncology Educational Book.
The advent of more effective treatment combinations for metastatic hormone-sensitive prostate cancer (mHSPC) has been built on successes in therapy development for metastatic, castration-resistant prostate cancer (mCRPC). Both disease phases hold sim
PDF file - 103K, Supplemental Figure 1. Frequency of HIBCH alteration across different studies available on cBioPortal for Cancer Genomics (http://www.cbioportal.org/public-portal/cross_cancer.do?).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7dad4ba387202cea1154a55f1162747d
https://doi.org/10.1158/2326-6066.22537576.v1
https://doi.org/10.1158/2326-6066.22537576.v1
We present the case of a man with metastatic, castration-resistant prostate cancer, who had a complete prostate-specific antigen (PSA) response after 2½ doses of ipilimumab. His treatment course was complicated by diarrhea and autoimmune hepatitis,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5eeda609a5d994e365bd2860ae549136
https://doi.org/10.1158/2326-6066.c.6548482.v1
https://doi.org/10.1158/2326-6066.c.6548482.v1
Autor:
Lisa N. Chesner, Julie N. Graff, Fanny Polesso, Alexis Smith, Arian Lundberg, Rajdeep Das, Tanushree Shenoy, Zheng Xia, Ya-Mei Hu, Martin Sjöström, Simon Linder, William S. Chen, Adam Foye, Haolong Li, Lisa Kim, Megha Bhalla, Thomas O’loughlin, Duygu Kuzuoglu-Ozturk, Tony Hua, Scott Wilkinson, Shana Y. Trostel, Andries M. Bergman, Davide Ruggero, Charles G. Drake, Adam G. Sowalsky, Lawrence Fong, Matthew Cooperberg, Alan Ashworth, Wilbert Zwart, David A. Quigley, Luke A. Gilbert, Amy E. Moran, Felix Feng
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35bbf5cfd907c6a3832de922c9b80633
https://doi.org/10.2139/ssrn.4403436
https://doi.org/10.2139/ssrn.4403436